Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix,

Slides:

Advertisements

Similar presentations

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

Advertisements

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort Michèle Beau-Faller, MD,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

High-Fidelity DNA Polymerase Enhances the Sensitivity of a Peptide Nucleic Acid Clamp PCR Assay for K-ras Mutations Bjørnar Gilje, Reino Heikkilä, Satu.

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of.

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Electronic Updates for JTO Readers

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Dramatic Response to Pemetrexed in a Patient with Pneumonic-Type Mucinous Bronchioloalveolar Carcinoma David H. Garfield, MD, Wilbur Franklin, MD Journal.

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

Development of a Quantitative Real-Time Polymerase Chain Reaction Assay for the Detection of the JAK2 V617F Mutation Elizabeth C. Wolstencroft, Katy.

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell.

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer Yasushi Yatabe, Toyoaki Hida, Yoshitsugu Horio, Takayuki.

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell.

MiR-205 and MiR-375 MicroRNA Assays to Distinguish Squamous Cell Carcinoma from Adenocarcinoma in Lung Cancer Biopsies Santosh Patnaik, MD, PhD, Reema.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

CtDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study Martin Reck, MD, PhD, Koichi Hagiwara,

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung.

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib Nuria Chic, MD Journal of Thoracic.

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

First Case of A859T Epidermal Growth Factor Receptor Mutation Responding to Erlotinib Laureline Le Maignan, BM, Delphine Mirebeau-Prunier, MD, PhD, Laurent.

Chien-Wei Chen, MD, Chin-Wei Kuo, MD Journal of Thoracic Oncology

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma Christoph Kneip, PhD, Bernd Schmidt, MD, Anke Seegebarth, Sabine Weickmann,

Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas Qiulu Pan, William Pao, Marc.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV: A Diagnosis Worth Making Todd M. Erickson,

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

S-1 Treatment for Chemorefractory Thymic Carcinoma

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity Chiyuki.

A Review of First-Line Treatment for Small-cell Lung Cancer

Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient Vincent Fallet, MD, Anne-Marie.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix, MD, PhD, Michèle Beau-Faller, MD, PhD Journal of Thoracic Oncology Volume 6, Issue 9, Pages 1615-1616 (September 2011) DOI: 10.1097/JTO.0b013e31822956bc Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Real-time peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping assay for EGFR T790M mutation detection. Delta-delta computed tomography (CT) values (in ordered) of PNA-mediated PCR clamping are calculated from 10 independent serially diluting DNA (1%, 10%, 100%) of H1975-mutant cell line (EGFR T790M heterozygous mutation) into the DNA of HT29 wild-type EGFR cell line. Box plots represented delta-delta CT values with gray boxes (median and IC range [25–75]), bars (IC 5–95), and extreme values with no overlap value between the different cell line dilutions. Delta-delta CT values for bronchial biopsy (BB) containing 5% of tumor cells and paired bronchioloalveolar lavage (BAL) of a patient with adenocarcinoma with bronchioloalveolar carcinoma feature (ADC-WBF) are indicated. Journal of Thoracic Oncology 2011 6, 1615-1616DOI: (10.1097/JTO.0b013e31822956bc) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions